PaRftZLfx方案在难治性肺结核中的应用效果评价

打开文本图片集

Evaluation of the Application Efect of PaRftZLfx Regimen in Refractory Pulmonary Tuberculosis/ HUANG Ziqiang， ZHU Jing， ZHANG She， WU Junjie. //Medical Innovation of China， 2025， 22（11）： 144-148

[Abstract]Objective： To explore the value of PaRfZLfx regimen in the treatment of refractory pulmonary tuberculosis.Method：Atotal of 80patients withrefractorypulmonarytuberculosiswereselected， allof whom were admitted to the Department of Lung Disease of Yangzhou Third People's Hospital from February 2022 to October 2023.They were randomly divided into two groups according to the random number method.The control group （40 cases） received LfxEPAS chemotherapy regimen， while the observation group （40 cases）received PaRfZLfx treatment.The clinical eficacy after3 months of treatment，sputumconversionrate after 2， 4，and 6 monthsof treatment，cavityclosure after 6 months oftreatment， incidence ofadverse reactionswithin 3 months，and changes in immune functionafter 3 monthsof treatment were compared.Result：The totaleffctiverate，sputum conversion rate，andcavityclosure intheobservation groupwere allbeterthanthose inthecontrol group，thediffrences were statistically significant （ P <0.05）.The incidence of adverse reactions in the observation group was lower than that in the control group， the difference was statistically significant （ P<0.05 . Compared with before treatment， CD ， CD CD4+/CD8 in both groups increased significantly after 3 months of treatment， while CD decreased significantly， the observation group were superior to the control group，the diferences were statistically significant （ P <0.05）.

Conclusion： Choosing PaRftZLfx in the treatment of refractory pulmonary tuberculosis can improve cavity closure， sputum conversion rate， ensure treatment effectiveness and safety， and enhance immune function.

[Key words] Rifapentine Refractory pulmonary tuberculosis Cavity closure Sputum conversion

First-author's address： Department of Lung Disease， Yangzhou Third People's Hospital， Yangzhou 225125， China

doi：10.3969/j.issn.1674-4985.2025.11.032

肺结核是由结核分枝杆菌感染后引起的肺部慢性传染性疾病，且为结核病中最常见的一种类型，若肺结核患者在经过多次治疗之后未得到明显的治疗效果，同时导致肺结核主要的感染菌已经对一些常用的药物产生严重的耐药性，此时可判定为难治性肺结核。（剩余6053字）